Mereo BioPharma’s Richard Bungay is set to step down from his roles as chief financial officer and chief operating officer in April 2017.
Bungay joined the UK-based clinical stage biopharmaceutical firm in July last year, taking on responsibility for Mereo BioPharma’s finances, manufacturing and quality operations.
He has previously held the chief financial title at Glide Pharmaceutical Technologies, Chroma Therapeutics and Verona Pharma, remaining as a non-executive board director at both Glide and Chroma.
Prior to these roles, Bungay worked at Celltech Group as director of corporate communications and planning, and served as finance director for AstraZeneca’s respiratory and inflammation therapy area.
Dr Peter Fellner, chairman of Mereo BioPharma, said: “On behalf of the board I would like to thank Richard for his significant contributions to the successful launch of the company and the subsequent introduction of its shares on AIM.
“We wish him every success for the future.”